Background: Practices to detect and manage hyperbilirubinemia in newborn nurseries are highly variable. American Academy of Pediatrics guidelines in 1999, 2004, and 2009 have generated, perhaps unintentionally, divergent practices that might not all be of equivalent value. Evidence-based progress is needed to define less invasive, less expensive, uniform, and safe methods to reduce ER visits and hospital readmissions for jaundice treatment and bilirubin encephalopathy. Objectives: This research briefing is intended to inform readers of a new prospective quality improvement program aimed at testing the value of specific changes in newborn nursery hyperbilirubinemia detection and management. This new program includes predetermined means of assessing those specific changes, which relate to diagnosis, safety, outcomes, and cost. Methods: In this briefing, we present the perceived problems in our present bilirubin management system, as voiced by stakeholders. We report our proposed means to test minimization of those problems utilizing already acquired data on approximately 400,000 well babies in the Intermountain Healthcare system of hospitals in the western USA. We then describe our methods of assessing specific outcomes in a pre- versus postpractice change analysis. Results and Conclusions: The University of Utah Newborn Nursery will implement a quality improvement project in bilirubin management during 2020 to test the feasibility and effectiveness of several changes to our current bilirubin management program. We maintain that the improved understanding generated by this project will be a step toward new evidence-based strategies for reducing ER visits and hospital readmissions for jaundice treatment and preventing bilirubin encephalopathy.

1.
American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia
.
Practice parameter: management of hyperbilirubinemia in the healthy term newborn
.
Pediatrics
.
1994
Oct
;
94
(
4 Pt 1
):
558
65
.
[PubMed]
0031-4005
2.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia
.
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation
.
Pediatrics
.
2004
Jul
;
114
(
1
):
297
316
.
[PubMed]
0031-4005
3.
Maisels
MJ
,
Bhutani
VK
,
Bogen
D
,
Newman
TB
,
Stark
AR
,
Watchko
JF
.
Hyperbilirubinemia in the newborn infant [{GT}] or =35 weeks’ gestation: an update with clarifications
.
Pediatrics
.
2009
Oct
;
124
(
4
):
1193
8
.
[PubMed]
0031-4005
4.
Shah
MH
,
Ariff
S
,
Ali
SR
,
Chaudhry
RA
,
Lakhdir
MP
,
Qaiser
F
, et al
Quality improvement initiative using transcutaneous bilirubin nomogram to decrease serum bilirubin sampling in low-risk babies
.
BMJ Paediatr Open
.
2019
Apr
;
3
(
1
):
e000403
.
[PubMed]
2399-9772
5.
Christensen
RD
,
Baer
VL
,
MacQueen
BC
,
O’Brien
EA
,
Ilstrup
SJ
.
ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program
.
J Perinatol
.
2018
May
;
38
(
5
):
517
25
.
[PubMed]
0743-8346
6.
Lieberman
L
,
Spradbrow
J
,
Keir
A
,
Dunn
M
,
Lin
Y
,
Callum
J
.
Use of intravenous immunoglobulin in neonates at a tertiary academic hospital: a retrospective 11-year study
.
Transfusion
.
2016
Nov
;
56
(
11
):
2704
11
.
[PubMed]
0041-1132
7.
Evanovitch
D
,
Clarke
G
,
Lieberman
L
,
Wilson
A
,
Sheuermann
S
.
Abstract Presentations from the AABB Annual Meeting San Antonio, TX, October 19–22, 2019
.
Transfus (Paris)
.
2019
Sep
;
59
S3
: 0372-1248
8.
Baer
VL
.
Absence of severe neonatal ABO hemolytic disease at Intermountain Healthcare.
■■■
9.
Newman
TB
,
Wickremasinghe
AC
,
Walsh
EM
,
Grimes
BA
,
McCulloch
CE
,
Kuzniewicz
MW
.
Retrospective Cohort Study of Phototherapy and Childhood Cancer in Northern California
.
Pediatrics
.
2016
Jun
;
137
(
6
):
e20151354
.
[PubMed]
0031-4005
10.
Kuzniewicz
MW
,
Niki
H
,
Walsh
EM
,
McCulloch
CE
,
Newman
TB
.
Hyperbilirubinemia, Phototherapy, and Childhood Asthma
.
Pediatrics
.
2018
Oct
;
142
(
4
):
e20180662
.
[PubMed]
0031-4005
11.
Newman
TB
,
Wu
YW
,
Kuzniewicz
MW
,
Grimes
BA
,
McCulloch
CE
.
Childhood Seizures After Phototherapy
.
Pediatrics
.
2018
Oct
;
142
(
4
):
e20180648
.
[PubMed]
0031-4005
12.
Kuzniewicz
MW
.
Impact of Universal Bilirubin Screening on Severe Hyperbilirubinemia and Phototherapy Use.
2019
;
124
:
11
.
13.
Kuzniewicz
MW
,
Greene
DN
,
Walsh
EM
,
McCulloch
CE
,
Newman
TB
.
Association Between Laboratory Calibration of a Serum Bilirubin Assay, Neonatal Bilirubin Levels, and Phototherapy Use
.
JAMA Pediatr
.
2016
Jun
;
170
(
6
):
557
61
.
[PubMed]
2168-6203
14.
Maisels
MJ
,
Deridder
JM
,
Kring
EA
,
Balasubramaniam
M
.
Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia
.
J Perinatol
.
2009
Sep
;
29
(
9
):
612
7
.
[PubMed]
0743-8346
15.
Taylor
JA
,
Burgos
AE
,
Flaherman
V
,
Chung
EK
,
Simpson
EA
,
Goyal
NK
, et al;
Better Outcomes through Research for Newborns Network
.
Discrepancies between transcutaneous and serum bilirubin measurements
.
Pediatrics
.
2015
Feb
;
135
(
2
):
224
31
.
[PubMed]
0031-4005
16.
Fonseca
R
,
Kyralessa
R
,
Malloy
M
,
Richardson
J
,
Jain
SK
.
Covered skin transcutaneous bilirubin estimation is comparable with serum bilirubin during and after phototherapy
.
J Perinatol
.
2012
Feb
;
32
(
2
):
129
31
.
[PubMed]
0743-8346
17.
Bahr
B
,
Timothy
M
,
Henry
E
,
Hulse
WN
,
Baer
VL
,
Prchal
JT
, et al
Early Hyperbilirubinemia in Neonates with Down Syndrome
.
J Pediatr
. Forthcoming
2019
Nov
.0022-3476
18.
Tidmarsh
GF
,
Wong
RJ
,
Stevenson
DK
.
End-tidal carbon monoxide and hemolysis
.
J Perinatol
.
2014
Aug
;
34
(
8
):
577
81
.
[PubMed]
0743-8346
19.
Bhutani
VK
,
Maisels
MJ
,
Schutzman
DL
,
Castillo Cuadrado
ME
,
Aby
JL
,
Bogen
DL
, et al
Identification of risk for neonatal haemolysis
.
Acta Paediatr
.
2018
Aug
;
107
(
8
):
1350
6
.
[PubMed]
0803-5253
20.
Christensen
RD
,
Malleske
DT
,
Lambert
DK
,
Baer
VL
,
Prchal
JT
,
Denson
LE
, et al
Measuring End-Tidal Carbon Monoxide of Jaundiced Neonates in the Birth Hospital to Identify Those with Hemolysis
.
Neonatology
.
2016
;
109
(
1
):
1
5
.
[PubMed]
1661-7800
21.
Christensen
RD
,
Lambert
DK
,
Henry
E
,
Yaish
HM
,
Prchal
JT
.
End-tidal carbon monoxide as an indicator of the hemolytic rate
.
Blood Cells Mol Dis
.
2015
Mar
;
54
(
3
):
292
6
.
[PubMed]
1079-9796
22.
Lau
SP
,
Fung
KP
.
Serum bilirubin kinetics in intermittent phototherapy of physiological jaundice
.
Arch Dis Child
.
1984
Sep
;
59
(
9
):
892
4
.
[PubMed]
0003-9888
23.
Sachdeva
M
,
Murki
S
,
Oleti
TP
,
Kandraju
H
.
Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 34 weeks of gestational age: a randomized controlled trial
.
Eur J Pediatr
.
2015
Feb
;
174
(
2
):
177
81
.
[PubMed]
0340-6199
24.
Zhou
S
,
Wu
X
,
Ma
A
,
Zhang
M
,
Liu
Y
.
Analysis of therapeutic effect of intermittent and continuous phototherapy on neonatal hemolytic jaundice
.
Exp Ther Med
.
2019
May
;
17
(
5
):
4007
12
.
[PubMed]
1792-0981
25.
Kawamoto
K
,
Kukhareva
P
,
Shakib
JH
,
Kramer
H
,
Rodriguez
S
,
Warner
PB
, et al
Association of an Electronic Health Record Add-on App for Neonatal Bilirubin Management With Physician Efficiency and Care Quality
.
JAMA Netw Open
.
2019
Nov
;
2
(
11
):
e1915343
.
[PubMed]
2574-3805
26.
Shakib
J
,
Buchi
K
,
Smith
E
,
Korgenski
K
,
Young
PC
.
Timing of initial well-child visit and readmissions of newborns
.
Pediatrics
.
2015
Mar
;
135
(
3
):
469
74
.
[PubMed]
0031-4005
27.
Christensen
RD
,
Agarwal
AM
,
George
TI
,
Bhutani
VK
,
Yaish
HM
.
Acute neonatal bilirubin encephalopathy in the State of Utah 2009-2018
.
Blood Cells Mol Dis
.
2018
Sep
;
72
:
10
3
.
[PubMed]
1079-9796
28.
Olusanya
BO
,
Kaplan
M
,
Hansen
TW
.
Neonatal hyperbilirubinaemia: a global perspective
.
Lancet Child Adolesc Health
.
2018
Aug
;
2
(
8
):
610
20
.
[PubMed]
2352-4650
29.
Grosse
SD
,
Prosser
LA
,
Botkin
JR
.
Screening for Neonatal Hyperbilirubinemia-First Do No Harm?
JAMA Pediatr
.
2019
Jul
;
173
(
7
):
617
8
.
[PubMed]
2168-6203
30.
Jackson
JC
.
Adverse events associated with exchange transfusion in healthy and ill newborns
.
Pediatrics
.
1997
May
;
99
(
5
):
E7
.
[PubMed]
0031-4005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.